2024
Understanding and overcoming resistance to immunotherapy in genitourinary cancers
Evans S, Jani Y, Jansen C, Yildirim A, Kalemoglu E, Bilen M. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biology & Therapy 2024, 25: 2342599. PMID: 38629578, PMCID: PMC11028033, DOI: 10.1080/15384047.2024.2342599.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsB7-H1 AntigenHumansImmunotherapyNeoplasmsNivolumabUrogenital NeoplasmsConceptsImmune checkpoint inhibitorsResistance to immunotherapyImmunotherapy resistanceTargeted therapyGenitourinary (GU) cancersCombined immune checkpoint inhibitorsIntroduction of novel immunotherapiesMechanisms of immunotherapy resistanceOvercome resistance to immunotherapyCancer cellsHost immune profileResponse to immunotherapyNovel targeted therapiesImmune system's rolePredictors of responseAttack cancer cellsImmune system's abilityStandard of careCheckpoint inhibitorsSequential therapyNovel immunotherapiesCombination therapyTreatment failureGU cancersTreatment landscape
2022
CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor
Prokhnevska N, Cardenas M, Valanparambil R, Sobierajska E, Barwick B, Jansen C, Reyes Moon A, Gregorova P, delBalzo L, Greenwald R, Bilen M, Alemozaffar M, Joshi S, Cimmino C, Larsen C, Master V, Sanda M, Kissick H. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity 2022, 56: 107-124.e5. PMID: 36580918, PMCID: PMC10266440, DOI: 10.1016/j.immuni.2022.12.002.Peer-Reviewed Original ResearchConceptsTumor-draining lymph nodesCD8<sup>+</sup> T cell activationT cell activationCD8<sup>+</sup> T cellsStem-like cellsT cellsCell activationEffector differentiationLymph nodesTumor-specific CD8<sup>+</sup> T cellsActivated CD8<sup>+</sup> T cellsAnti-tumor T cell responsesTumor-draining lymph node cellsCD8+ T cell activationCo-stimulationT cell responsesAntigen-presenting cellsMurine tumor modelsResponse to cancerEffector phenotypeTumor immunotherapyTumor modelTumorCell responsesAcute viruses
2020
Considerations for cancer immunotherapy biomarker research during COVID-19
Carlisle J, Jansen C, Bilen M, Kissick H. Considerations for cancer immunotherapy biomarker research during COVID-19. Endocrine Related Cancer 2020, -1: c1-c8. PMID: 32508308, PMCID: PMC7385701, DOI: 10.1530/erc-20-0187.Peer-Reviewed Original Research
2019
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Jansen C, Prokhnevska N, Master V, Sanda M, Carlisle J, Bilen M, Cardenas M, Wilkinson S, Lake R, Sowalsky A, Valanparambil R, Hudson W, McGuire D, Melnick K, Khan A, Kim K, Chang Y, Kim A, Filson C, Alemozaffar M, Osunkoya A, Mullane P, Ellis C, Akondy R, Im S, Kamphorst A, Reyes A, Liu Y, Kissick H. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 2019, 576: 465-470. PMID: 31827286, PMCID: PMC7108171, DOI: 10.1038/s41586-019-1836-5.Peer-Reviewed Original ResearchConceptsCD8 T cellsStem-like CD8 T cellsT cellsStem-like T cellsCD8 T cell infiltrationCD8 T cell responsesMechanism of immune escapeTumor-infiltrating lymphocytesT cell infiltrationT cell responsesStem-like cellsSurvival benefitImmune nicheProgressive diseaseImmune escapeTumor typesTumorCD8Human cancersDifferentiation processLymphocytesPatientsCancerInfiltrationSurvival